| Browse All

Gossamer Bio, Inc. (GOSS)

Healthcare | Biotechnology | San Diego, United States | NasdaqGS
0.42 USD -0.03 (-5.830%) ⇩ (April 20, 2026, 4 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 19, 2026, 12:18 a.m. EDT

Despite narratives of a 'bottom' and strong revenue growth, founder notes below on Gossamer Bio (GOSS) are uninvestable today. The fundamental data reveals a capital-destroying operational business in distress: negative EPS, negative operating margins, negative free cash flow, and a book value of -0.52. The company is drowning in debt (202M) exceeding its cash (136M), creating a precarious liquidity situation. While the price has dropped 85% recently, aligning with a Phase 3 setback, there is no cushion left; another catalyst failure will likely trigger technical bankruptcy rather than a bounce. The lack of dividend and negative sales metrics confirm this is an avoid trap, not a value opportunity.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓1.338154
AutoARIMA1.349826
AutoETS1.352348
MSTL1.377443

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 32%
H-stat 8.11
Ljung-Box p 0.000
Jarque-Bera p 0.019
Excess Kurtosis -1.15
Attribute Value
Sector Healthcare
Revenue per Share 0.212
Market Cap 98,572,440
Forward P/E -2.51
Beta 2.16
Website https://www.gossamerbio.com

As of April 19, 2026, 12:18 a.m. EDT: Options flow indicates a distinct lack of naked call volume at strikes above the current price (0.446), with zero reported open interest for ITM puts at 45-day and 2-month expirations. However, there is a concentrated 'unger' (insurance) position where significant Call OI and Put OI pile up at strikes 3.0 and 7.0 for 2026-2028 expirations, suggesting an activist or bullish positioning thesis. Conversely, significant In-the-Money Put volume at strikes 0.5 and 1.5 for expirations under 6 months suggests active hedge buying or bearish hedging by long positions, while ATM call IV remains low (4.5%) indicating low immediate volatility expectations among speculators.


Info Dump

Attribute Value
52 Week Change -0.4921403
Address1 3,115 Merryfield Row
Address2 Suite 120
All Time High 27.15
All Time Low 0.32
Ask 0.5447
Ask Size 2
Audit Risk 5
Average Daily Volume10 Day 7,141,960
Average Daily Volume3 Month 16,412,181
Average Volume 16,412,181
Average Volume10Days 7,141,960
Beta 2.159
Bid 0.318
Bid Size 2
Board Risk 8
Book Value -0.525
City San Diego
Compensation As Of Epoch Date 1,735,603,200
Compensation Risk 9
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.42
Current Ratio 2.643
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 0.46
Day Low 0.4143
Display Name Gossamer Bio
Earnings Call Timestamp End 1,747,341,000
Earnings Call Timestamp Start 1,747,341,000
Earnings Timestamp 1,773,777,600
Earnings Timestamp End 1,778,788,800
Earnings Timestamp Start 1,778,788,800
Ebitda -163,228,992
Ebitda Margins 0.0
Enterprise To Ebitda -1.008
Enterprise To Revenue 3.395
Enterprise Value 164,546,432
Eps Current Year -0.489
Eps Forward -0.167
Eps Trailing Twelve Months -0.75
Esg Populated 0
Exchange NMS
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 0.784
Fifty Day Average Change -0.364
Fifty Day Average Change Percent -0.46428573
Fifty Two Week Change Percent -49.214027
Fifty Two Week High 3.87
Fifty Two Week High Change -3.4499998
Fifty Two Week High Change Percent -0.8914728
Fifty Two Week Low 0.32
Fifty Two Week Low Change 0.099999994
Fifty Two Week Low Change Percent 0.3125
Fifty Two Week Range 0.32 - 3.87
Financial Currency USD
First Trade Date Milliseconds 1,549,636,200,000
Float Shares 211,156,244
Forward Eps -0.167
Forward P E -2.51497
Free Cashflow -93,332,248
Full Exchange Name NasdaqGS
Full Time Employees 161
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins 1.0
Gross Profits 48,471,000
Has Pre Post Market Data 1
Held Percent Insiders 0.0416
Held Percent Institutions 0.72890997
Implied Shares Outstanding 234,696,281
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Long Business Summary Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Long Name Gossamer Bio, Inc.
Market us_market
Market Cap 98,572,440
Market State PRE
Max Age 86,400
Message Board Id finmb_548541911
Most Recent Quarter 1,767,139,200
Net Income To Common -170,370,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 98,572,438
Number Of Analyst Opinions 7
Open 0.4391
Operating Cashflow -171,266,000
Operating Margins -3.3364701
Overall Risk 8
Payout Ratio 0.0
Phone 858 684 1300
Pre Market Change -0.007999986
Pre Market Change Percent -1.9047587
Pre Market Price 0.412
Pre Market Time 1,776,776,675
Previous Close 0.446
Price Eps Current Year -0.8588957
Price Hint 4
Price To Book -0.8
Price To Sales Trailing12 Months 2.0336375
Profit Margins 0.0
Quick Ratio 2.356
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.026
Regular Market Change Percent -5.8296
Regular Market Day High 0.46
Regular Market Day Low 0.4143
Regular Market Day Range 0.4143 - 0.46
Regular Market Open 0.4391
Regular Market Previous Close 0.446
Regular Market Price 0.42
Regular Market Time 1,776,715,201
Regular Market Volume 4,480,509
Return On Assets -0.41856
Revenue Growth 0.471
Revenue Per Share 0.212
Sand P52 Week Change 0.34445214
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 8
Shares Outstanding 234,696,281
Shares Percent Shares Out 0.1598
Shares Short 37,500,300
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 34,715,538
Short Name Gossamer Bio, Inc.
Short Percent Of Float 0.1697
Short Ratio 2.74
Source Interval 15
State CA
Symbol GOSS
Target High Price 15.0
Target Low Price 0.3
Target Mean Price 3.68571
Target Median Price 1.0
Total Cash 136,932,000
Total Cash Per Share 0.583
Total Debt 202,906,000
Total Revenue 48,471,000
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -0.75
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 2.111075
Two Hundred Day Average Change -1.691075
Two Hundred Day Average Change Percent -0.80104923
Type Disp Equity
Volume 4,480,509
Website https://www.gossamerbio.com
Zip 92,121